I agree to all those posters who said that there is no further news to wait for after the full data from the HSV-2 Phase 1 study are released this quarter.........
.......oh wait..... I forgot these items below. How silly of me to forget even though they were previous published a couple of times yesterday in this forum.
- Extending the use of CardioCel® for an expanded range of indications in cardiovascular surgery;
- Expanding regenerative tissue portfolio and explore the use of ADAPT® prepared tissue for additional surgical applications that have the potential to increase revenue in the future;
- Initial Asian market approval for CardioCel®;
- Initiation of HSV-2 Phase II; and
- Initiation of HPV Phase I.
I agree to all those posters who said that there is no further...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.10 |
Change
0.190(1.06%) |
Mkt cap ! $344.2M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $18.00 | $22.76K | 1.264K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 758 | $17.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.05 | 200 | 1 |
View Market Depth
| Last trade - 10.27am 16/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |